ROS-responsive charge reversal mesoporous silica nanoparticles as promising drug delivery system for neovascular retinal diseases
Open Access
- 17 July 2024
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 373, 224-239
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologiesAdvanced Drug Delivery Reviews, 2022
- Biomedical and Pharmacological Uses of Fluorescein Isothiocyanate Chitosan‐Based NanocarriersMacromolecular Bioscience, 2020
- Protein Stability and Photostability under In Vitro Vitreal Conditions - Implications for Long Acting Delivery of Protein Therapeutics for Ocular DiseasePharmaceutical Research, 2020
- Glycosaminoglycans from bovine eye vitreous humour and interaction with collagen type IIGlycoconjugate Journal, 2018
- Degradability and Clearance of Silicon, Organosilica, Silsesquioxane, Silica Mixed Oxide, and Mesoporous Silica NanoparticlesAdvanced Materials, 2017
- Diffusion Regulation in the Vitreous HumorBiophysical Journal, 2015
- Cancer‐Cell‐Specific Nuclear‐Targeted Drug Delivery by Dual‐Ligand‐Modified Mesoporous Silica NanoparticlesSmall, 2015
- The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injectionBiomaterials, 2012
- VEGF-Mediated STAT3 Activation Inhibits Retinal Vascularization by Down-Regulating Local Erythropoietin ExpressionThe American Journal of Pathology, 2012
- Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cellsDiabetologia, 2011